Physician profile
John L Anthony
NPI 1184790479
$18,888.20
in general payments reported to CMS, 2019-2025
37 companies · $3,742 in 2025
The $3,742 reported for 2025 was more than what 87% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,736 · 2020: $1,484 · 2021: $2,175 · 2022: $2,807 · 2023: $3,556 · 2024: $3,388 · 2025: $3,742.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $72.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,614.20 |
| Education | $72.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,150.39 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Janssen Biotech, INC. | $2,194.23 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Novartis Pharmaceuticals Corporation | $1,823.00 | 2019-2025 | |
| Ucb, INC. | $1,495.24 | 2019-2025 | Bimzelx, Cimzia |
| Regeneron Healthcare Solutions, INC. | $1,469.80 | 2019-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $1,240.92 | 2019-2025 | |
| Lilly USA, LLC | $973.46 | 2019-2025 | Taltz, Ebglyss |
| Amgen INC. | $861.48 | 2019-2025 | Otezla, Otezla |
| E.R. Squibb & Sons, L.L.C. | $700.40 | 2022-2025 | Sotyktu |
| Pfizer INC. | $548.38 | 2019-2025 | |
| Leo Pharma INC. | $432.50 | 2020-2025 | Adbry, Anzupgo |
| Sun Pharmaceutical Industries INC. | $323.96 | 2019-2020 | |
| Incyte Corporation | $286.26 | 2022-2025 | Opzelura |
| Arcutis Biotherapeutics, INC. | $257.73 | 2023-2025 | Zoryve |
| Dermavant Sciences, INC. | $235.60 | 2023-2024 | Vtama |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $235.10 | 2019-2023 | Jublia, Arazlo, Duobrii |
| Janssen Scientific Affairs, LLC | $205.22 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $173.73 | 2022-2025 | Spevigo, Cyltezo |
| Organon LLC | $171.58 | 2025 | Vtama |
| Galderma Laboratories, L.P. | $170.59 | 2021-2025 | Nemluvio, Aklief, Epsolay |
| Kyowa Kirin, INC. | $165.58 | 2020-2025 | |
| Dermira, INC. | $139.36 | 2019-2021 | |
| Celgene Corporation | $118.12 | 2019 | |
| Sanofi-Aventis U.S. LLC | $92.69 | 2021-2022 | |
| Helsinn Therapeutics (U.S.), INC. | $65.46 | 2021-2023 | Valchlor |
| Epi Health, LLC | $50.98 | 2021-2022 | |
| Vyne Pharmaceuticals INC. | $49.98 | 2020-2021 | |
| Mayne Pharma Commercial LLC | $49.36 | 2019-2025 | |
| Biofrontera INC. | $43.18 | 2024 | Ameluz, Xepi, Bf-Rhodoled |
| Genentech USA, INC. | $38.02 | 2019-2024 | Erivedge |
| Almirall LLC | $26.85 | 2019 | |
| Dusa Pharmaceuticals, INC. | $20.66 | 2019 | |
| Verrica Pharmaceuticals INC. | $17.95 | 2024 | Ycanth |
| Mission Pharmacal Company | $16.46 | 2019 | |
| Botanix Sb INC | $15.66 | 2025 | Sofdra |
| Sandoz INC. | $14.78 | 2023 | Hyrimoz |
| Paratek Pharmaceuticals, INC. | $13.54 | 2024 | Nuzyra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Anthony listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.